Dual Antiviral Therapy for Persistent Coronavirus Disease 2019 and Associated Organizing Pneumonia in an Immunocompromised Host

Caitlin A Trottier; Beverly Wong; Rakhi Kohli; Cassidy Boomsma; Francis Magro; Sucharita Kher; Christina Anderlind; Yoav Golan

doi:10.1093/cid/ciac847

Dual Antiviral Therapy for Persistent Coronavirus Disease 2019 and Associated Organizing Pneumonia in an Immunocompromised Host

Clin Infect Dis. 2023 Mar 4;76(5):923-925. doi: 10.1093/cid/ciac847.

Authors

Caitlin A Trottier¹, Beverly Wong², Rakhi Kohli^{1

3}, Cassidy Boomsma³, Francis Magro⁴, Sucharita Kher^{2

3}, Christina Anderlind^{2

3}, Yoav Golan^{1

3}

Affiliations

¹ Department of Medicine, Division of Geographic Medicine and Infectious Diseases, Boston, Massachusetts, USA.
² Department of Medicine, Division of Pulmonary and Critical Care, Tufts Medical Center, Boston, Massachusetts, USA.
³ Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA.
⁴ Department of Medicine, Division of Infectious Diseases, Lowell General Hospital, Lowell, Massachusetts, USA.

Abstract

The management of patients with prolonged viral shedding and coronavirus disease 2019 symptoms remains unclear. Combining antivirals, as practiced in other infections, is theoretically advantageous. We present a case of persistent, symptomatic severe acute respiratory syndrome coronavirus 2 infection and associated organizing pneumonia that was successfully treated with an extended course of combination antiviral therapy.

Keywords: COVID-19; SARS-CoV-2; immunocompromise.

Publication types

Case Reports

MeSH terms

Antiviral Agents / therapeutic use
COVID-19*
Humans
Immunocompromised Host
Organizing Pneumonia*
SARS-CoV-2

Substances

Antiviral Agents